US Pharma MarketingKyverna begins rolling submission for autoimmune CAR-T as FDA requests more natural history analysis
Kyverna begins rolling submission for autoimmune CAR-T as FDA requests more natural history analysis is a pharma and life sciences industry update from FierceBiotech. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
Kyverna Therapeutics has officially started a rolling submission to the FDA for miv-cel as the company conducts additional natural history analysis at the agency's request, keeping the candidate on track to be the first autoimmune CAR-T to reach the market.
Source: FierceBiotech